STOK SEC Filing News — Stoke Therapeutics, Inc.

Latest SEC filings for Stoke Therapeutics, Inc. (STOK) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-02.

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational n…
Sector: Healthcare Industry: Biotechnology Market Cap: $1.6B
20
Total Filings
0
Bullish Classifications
9
Bearish Classifications
12
Insider Transactions
4
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for STOK currently lean bearish. Of the 20 filing records displayed, 9 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
STOK Filing Activity Snapshot 2026-06-18 — 2026-10-02
Insider Transactions (Form 4)
0 buys vs 9 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$605.1K
BARUCH TICHO · 2026-08-03
20,967 shares · Form 144
Form 144 Notices
3
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 12 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 12 filings in this group are Form 4s for Stoke Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 12 insider filings shown, the breakdown is 9 open-market sale, 2 compensation award and 1 gift. 9 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×9
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Compensation award ×2
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Gift ×1
Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.
Form 4 Open-market sale Insider Selling 2026-10-02

STOK insider Allan Jonathan (GENERAL COUNSEL & CORP SEC) sold 627 shares (~$16.5K)

Allan Jonathan, listed as GENERAL COUNSEL & CORP SEC at Stoke Therapeutics, Inc., reported an open-market sale of 627 STOK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 627 $26.33 $16.5K
Filing: Form 4 (Insider Transaction) Insider: Allan Jonathan (GENERAL COUNSEL & CORP SEC) Shares: 627 Est. Value: $16.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-10-02

STOK insider Ticho Barry (CHIEF MEDICAL OFFICER) sold 1,051 shares (~$27.5K)

Ticho Barry, listed as CHIEF MEDICAL OFFICER at Stoke Therapeutics, Inc., reported an open-market sale of 1,051 STOK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,051 $26.16 $27.5K
Filing: Form 4 (Insider Transaction) Insider: Ticho Barry (CHIEF MEDICAL OFFICER) Shares: 1,051 Est. Value: $27.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-09-25

STOK insider Form 4 filed for equity award, exercise, or tax withholding

Cumbo Alexander (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Director Stock Option (Right to Buy) 39,674 — —
Filing: Form 4 (Insider Transaction) Insider: Cumbo Alexander (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-09-03

STOK insider Ticho Barry (CHIEF MEDICAL OFFICER) sold 5,545 shares (~$170.1K)

Ticho Barry, listed as CHIEF MEDICAL OFFICER at Stoke Therapeutics, Inc., reported an open-market sale of 5,545 STOK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 3,945 $30.51 $120.4K
S Open-market sale 1,600 $31.06 $49.7K
Filing: Form 4 (Insider Transaction) Insider: Ticho Barry (CHIEF MEDICAL OFFICER) Shares: 5,545 Est. Value: $170.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-18

STOK insider Ticho Barry (CHIEF MEDICAL OFFICER) sold 4,767 shares (~$152.7K)

Ticho Barry, listed as CHIEF MEDICAL OFFICER at Stoke Therapeutics, Inc., reported an open-market sale of 4,767 STOK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 10,000 — —
S Open-market sale 4,525 $32.01 $144.8K
S Open-market sale 242 $32.47 $7.9K
M Option exercise derivative · Performance Stock Units 10,000 — —
Filing: Form 4 (Insider Transaction) Insider: Ticho Barry (CHIEF MEDICAL OFFICER) Shares: 4,767 Est. Value: $152.7K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-18

STOK insider Kaye Edward M. MD (Director) sold 12,567 shares (~$402.5K)

Kaye Edward M. MD, listed as Director at Stoke Therapeutics, Inc., reported an open-market sale of 12,567 STOK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 26,250 — —
S Open-market sale 11,930 $32.01 $381.8K
S Open-market sale 637 $32.47 $20.7K
M Option exercise derivative · Performance Stock Units 26,250 — —
Filing: Form 4 (Insider Transaction) Insider: Kaye Edward M. MD (Director) Shares: 12,567 Est. Value: $402.5K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-18

STOK insider Allan Jonathan (GENERAL COUNSEL & CORP SEC) sold 2,861 shares (~$91.6K)

Allan Jonathan, listed as GENERAL COUNSEL & CORP SEC at Stoke Therapeutics, Inc., reported an open-market sale of 2,861 STOK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 6,000 — —
S Open-market sale 2,716 $32.01 $86.9K
S Open-market sale 145 $32.47 $4.7K
M Option exercise derivative · Performance Stock Units 6,000 — —
Filing: Form 4 (Insider Transaction) Insider: Allan Jonathan (GENERAL COUNSEL & CORP SEC) Shares: 2,861 Est. Value: $91.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-05

STOK insider Ticho Barry (CHIEF MEDICAL OFFICER) sold 7,176 shares (~$208.4K)

Ticho Barry, listed as CHIEF MEDICAL OFFICER at Stoke Therapeutics, Inc., reported an open-market sale of 7,176 STOK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 5,907 $28.95 $171.0K
S Open-market sale 1,269 $29.45 $37.4K
Filing: Form 4 (Insider Transaction) Insider: Ticho Barry (CHIEF MEDICAL OFFICER) Shares: 7,176 Est. Value: $208.4K
View on SEC EDGAR → Open Filing Document →
Form 4 Gift Tax / Compensation Filing 2026-07-17

STOK insider Form 4 filed for equity award, exercise, or tax withholding

Harrison Seth Loring (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code Nature Shares Price Value
G Gift derivative · Stock Option (Right to Buy) 29,555 — —
G Gift derivative · Stock Option (Right to Buy) 29,555 — —
G Gift derivative · Stock Option (Right to Buy) 14,777 — —
G Gift derivative · Stock Option (Right to Buy) 14,777 — —
G Gift derivative · Stock Option (Right to Buy) 11,650 — —
G Gift derivative · Stock Option (Right to Buy) 11,650 — —
G Gift derivative · Stock Option (Right to Buy) 21,000 — —
G Gift derivative · Stock Option (Right to Buy) 21,000 — —
G Gift derivative · Stock Option (Right to Buy) 19,441 — —
G Gift derivative · Stock Option (Right to Buy) 19,441 — —
G Gift derivative · Stock Option (Right to Buy) 7,639 — —
G Gift derivative · Stock Option (Right to Buy) 7,639 — —
G Gift derivative · Stock Option (Right to Buy) 29,747 — —
G Gift derivative · Stock Option (Right to Buy) 29,747 — —
G Gift derivative · Stock Option (Right to Buy) 17,786 — —
G Gift derivative · Stock Option (Right to Buy) 17,786 — —
Filing: Form 4 (Insider Transaction) Insider: Harrison Seth Loring (Director)
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-17

STOK insider Form 4 filed for equity award, exercise, or tax withholding

McCauley Thomas (Chief Scientific Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Stock Option (Right to Buy) 225,000 — —
Filing: Form 4 (Insider Transaction) Insider: McCauley Thomas (Chief Scientific Officer)
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-06

STOK insider Ticho Barry (CHIEF MEDICAL OFFICER) sold 7,228 shares (~$236.1K)

Ticho Barry, listed as CHIEF MEDICAL OFFICER at Stoke Therapeutics, Inc., reported an open-market sale of 7,228 STOK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 6,728 $32.62 $219.4K
S Open-market sale 500 $33.27 $16.6K
Filing: Form 4 (Insider Transaction) Insider: Ticho Barry (CHIEF MEDICAL OFFICER) Shares: 7,228 Est. Value: $236.1K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-18

STOK insider Allan Jonathan (GENERAL COUNSEL & CORP SEC) sold 1,457 shares (~$43.6K)

Allan Jonathan, listed as GENERAL COUNSEL & CORP SEC at Stoke Therapeutics, Inc., reported an open-market sale of 1,457 STOK shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,457 $29.95 $43.6K
Filing: Form 4 (Insider Transaction) Insider: Allan Jonathan (GENERAL COUNSEL & CORP SEC) Shares: 1,457 Est. Value: $43.6K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Stoke Therapeutics, Inc. has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-10-02

STOK Form 144 filed for proposed insider sale by JONATHAN D ALLAN (627 shares) ~$16.3K

JONATHAN D ALLAN filed a Form 144 with the SEC indicating intent to sell STOK (Stoke Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JONATHAN D ALLAN Shares: 627 Est. Value: $16.3K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-03

STOK Form 144 filed for proposed insider sale by BARUCH TICHO (20,967 shares) ~$605.1K

BARUCH TICHO filed a Form 144 with the SEC indicating intent to sell STOK (Stoke Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: BARUCH TICHO Shares: 20,967 Est. Value: $605.1K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-01

STOK Form 144 filed for proposed insider sale by BARUCH S. TICHO (7,228 shares) ~$236.5K

BARUCH S. TICHO filed a Form 144 with the SEC indicating intent to sell STOK (Stoke Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: BARUCH S. TICHO Shares: 7,228 Est. Value: $236.5K
View on SEC EDGAR → Open Filing Document →
Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for Stoke Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-25

STOK filed 8-K — material company event

Stoke Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-03

STOK filed 8-K — material company event

Stoke Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-08-03

STOK filed 8-K — material company event

Stoke Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-30

STOK filed 8-K — material company event

Stoke Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Stoke Therapeutics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-03

STOK filed Quarterly Report (10-Q)

Stoke Therapeutics, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Stoke Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on STOK. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — STOK SEC Filings

More Tools for STOK

STOK Full Stock Analysis STOK Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper STOK analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the STOK stock analysis page.

STOK Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer